IRIS Biomedical

Salt Lake City, Utah, United StatesFounded 202011–50 employeesirismeddesign.comLinkedIn

Brain-computer interfaces
Neuromodulation

IRIS Biomedical is a neurotechnology original design manufacturer and a wholly owned subsidiary of Ripple Ventures. It develops and manufactures components and complete systems for neural sensing, stimulation, neuromodulation, and neurodiagnostics, serving medical device companies and clinical research teams.

Visit irismeddesign.com ↗

Founded: 2020
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

IRIS Biomedical’s profile centers on its work as a neurotechnology original design manufacturer developing components and complete systems for neural sensing, stimulation, neuromodulation, and neurodiagnostics. The company was founded in 2020, and Andrew Wilder has been listed as CEO since January 2020. Its stated offerings span closed-loop neural sensing and stimulation systems, wireless power delivery, data telemetry, portable signal processing, and original design manufacturing services. The company also describes in-house clean-room capabilities for development, prototyping, and early-stage production, alongside an ISO 13485-certified quality management system. Consequently, the clearest observable developments are the breadth of its technical offering and its positioning as a design-and-manufacturing partner rather than a company with a publicly detailed sequence of launches or financing events.

Market position

IRIS Biomedical operates in the specialized neurotechnology and medical-device development market. It describes itself as both a designer and manufacturer, serving medical-device companies and clinical research teams with components as well as complete-system development. Its product range includes closed-loop neural sensing and stimulation systems, wireless power components, telemetry modules, portable signal-processing units, and original design manufacturing services. The company’s stated technical capabilities include neural sensing and stimulation ASICs, high-bandwidth telemetry, wireless power transfer, hermetic ceramic and titanium packaging, and flexible custom neural leads. Its website also identifies ATHENA as an active implantable research platform and describes a modular system with MATLAB and Python APIs. These capabilities suggest a service and platform-oriented position: customers can draw on design, component engineering, packaging, and manufacturing rather than sourcing only a finished device. The company also highlights clean-room development and prototyping and an ISO 13485-certified quality management system, relevant to medical-device development. Its differentiation is best characterized by the combination of neural-interface engineering and manufacturing services.

Growth & opportunities

The company was founded on January 1, 2020, and Andrew Wilder has been listed as CEO since January 2020. Its described workforce band is 11–50 employees, without a dated employee history to show whether that level has changed. The clearest indicator of development is the breadth of its stated portfolio: closed-loop sensing and stimulation systems, wireless power and charging, telemetry, portable signal processing, and original design manufacturing. Its website also describes an active implantable research platform, custom neural leads, and a portable neurophysiology processing hub supporting up to 256 channels. These offerings indicate a range of technical work, but do not establish launch dates, customer adoption, production volume, or revenue growth.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes IRIS Biomedical distinct

reccy insights

What makes IRIS Biomedical distinct

01Offers both individual device components and complete-system design and manufacturing services.
02Combines neural sensing and stimulation technologies for closed-loop applications.
03Provides in-house clean-room facilities for development, prototyping, and early-stage commercial production.
04Designs are described as field-tested and adaptable to different device form factors.
05Performs design and manufacturing under an ISO 13485-certified Quality Management System.

Technology & products5

Technology & products

Closed-Loop Neural Sensing and Stimulation Systems
Systems designed to sense neural activity and provide stimulation in a closed-loop manner for medical device applications.
Wireless Power Delivery Components
Components that provide continuous wireless power transfer and inductive battery charging for medical devices.
Data Telemetry Modules
Modules that enable wireless data transmission for neural sensing and stimulation devices.
Portable Signal Processing Units
Portable devices that process neural signals for neurodiagnostic and neuromodulation applications.
Original Design Manufacturing (ODM) Services
Engineering and manufacturing services for developing neural sensing and stimulation medical devices.

Show all 5 products

+ 2 more: Portable Signal Processing Units, Original Design Manufacturing (ODM) Services

Similar companies

Show all 6 companies

About IRIS Biomedical

Products: Closed-Loop Neural Sensing and Stimulation Systems, Wireless Power Delivery Components, Data Telemetry Modules, Portable Signal Processing Units, Original Design Manufacturing (ODM) Services
Leadership: Andrew Wilder, CEO
Focus areas: Neurotechnology, medical devices, neuromodulation, neurodiagnostics, neural interfaces, clinical research, medical device manufacturing
Headquarters: Salt Lake City, Utah, United States
Founded: 2020
Employees: 11–50